A Phase 1, Single Centre, Single Dose, Double-Blind, Double-Dummy, Four-Way Crossover, Placebo-Controlled, Randomized Study to Investigate the Effects of AZD7325 on Sedation, Cognition and Electroencephalogram (EEG) in Comparison With Lorazepam in Healthy Male Volunteers.

Trial Profile

A Phase 1, Single Centre, Single Dose, Double-Blind, Double-Dummy, Four-Way Crossover, Placebo-Controlled, Randomized Study to Investigate the Effects of AZD7325 on Sedation, Cognition and Electroencephalogram (EEG) in Comparison With Lorazepam in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 May 2014

At a glance

  • Drugs AZD 7325 (Primary) ; Lorazepam
  • Indications Anxiety disorders; Depressive disorders; Epilepsy; Generalised anxiety disorder; Generalised seizures; Hepatitis C; Seizures; Social phobia; Status epilepticus
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 20 Nov 2008 Planned end date changed from 1 Aug 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.
    • 20 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top